- Drugs
- Thursday, 19 Sep 2019
Aphria Inc Launches Plant Positivity Social Impact Platform with Evergreen
Aphria Inc. announced the launch of its new social impact platform, Plant Positivity. The company partnered with not-for-profit Evergreen which will create six new garden spaces at Evergreen Brick Works.
Aphria, Inc. is engaged in the production and supply of medical cannabis. It operates through three reportable segments including cannabis operations, distribution operations, and business under development. The Cannabis Operations segment produces, distributes, and sells both medical and adult-use cannabis. The Distribution Operations segment are carried out through its wholly owned subsidiaries ABP, FL Group, and CC Pharma. The Distribution under Development segment includes operations in which the firm has not received final licensing or has not commenced commercial sales from operations. The company offers medical cannabis of various strains, including Kusawa, Tamaracouta, Panache, Churchill and Iroquois. The Company is also engaged in the research and development, and commercial production of cannabis oil. The company was founded by Cole Cacciavillani and John Cervini on June 22, 2011 and is headquartered in Leamington, Canada. Aphria’s subsidiaries include Pure Natures Wellness Inc. that are engaged in the production and distribution of medical marijuana, and Cannway Pharmaceuticals Ltd., which specializes in offering support services to veterans and their first responders.
Related Industry Updates
Australia & South Korea Diabetic Foot Ulcer Market is expected to reach US$ 313.53 billion by 2030
Sep 20, 2023
Teva and Blackstone Fund $400M to Advance duvakitug Clinical Growth
Mar 04, 2026
Paracetamol Market Growth: Innovations, Opportunities, and Competitive Landscape
Nov 21, 2025
India will ship nearly 1,000 tonnes of paracetamol raw material to Europe
May 06, 2020
Scientists hail dexamethasone as 'major breakthrough' in treating COVID-19
Jun 16, 2020
Europe pharmaceutical drug delivery market is expected to reach US$ 562,102.6 Mn by 2027
Oct 06, 2020
FDA Grants Avatrombopag Orphan Drug Designation for the Treatment of Chemotherapy-induced Thrombocytopenia
Dec 23, 2019